Open-label, Four-period, Randomized Crossover Study to Determine the Comparative Pharmacokinetics of Oral and Intravenous Acetaminophen Administration in Healthy Male Volunteers

Trial Profile

Open-label, Four-period, Randomized Crossover Study to Determine the Comparative Pharmacokinetics of Oral and Intravenous Acetaminophen Administration in Healthy Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2010

At a glance

  • Drugs Paracetamol (Primary) ; Paracetamol (Primary)
  • Indications Postoperative pain
  • Focus Pharmacokinetics; Registrational
  • Sponsors Cadence Pharmaceuticals
  • Most Recent Events

    • 02 Nov 2010 According to a Cadence Pharmaceuticals media release, the US FDA has approved OFIRMEV (IV parcetamol) for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever.
    • 21 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top